Clinical complete regression after local radiotherapy combined with chemotherapy for stage IV rectal cancer: A case report

Dang,Yazheng; Gao,Hongxiang; Huang,Shigao; Qi,Tao

doi:10.3892/mco.2020.2049

Clinical complete regression after local radiotherapy combined with chemotherapy for stage IV rectal cancer: A case report

Authors:
- Yazheng Dang
- Hongxiang Gao
- Shigao Huang
- Tao Qi
View Affiliations

Affiliations: Department of Radiation Oncology, 986 Hospital of People's Liberation Army Air Force, Xi'an, Shaanxi 710054, P.R. China, Department of Oncology, Chang An Hospital, Xi'an, Shaanxi 710018, P.R. China, Cancer Center, Faculty of Health Sciences, University of Macau, Taipa, Macao SAR 999078
Published online on: May 22, 2020 https://doi.org/10.3892/mco.2020.2049
Pages: 186-190

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer is the fourth most common type of cancer worldwide with about 0.8 million new cases annually. Improving patient survival remains a challenge for clinicians. Observation waiting method provides improved quality of life compared with direct surgery. This case report suggested that colorectal cancer patients could choose active observation waiting method for treatment. A 59‑year‑old male patient, with rectal bleeding and an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, was admitted to the hospital due to increased fecal blood volume. The electronic colonoscopy revealed multiple polyps in colon and rectum, whereas the pathological biopsy indicated poorly differentiated rectal adenocarcinoma. The clinical stage was defined as T3N2M1a according to the TNM classification of the American Joint Committee on Cancer (AJCC) staging manual (version 8). In addition, positron emission tomography/computed tomography (PET/CT) examination showed non‑regional lymph node metastasis (subclavian). Subsequently, the expression of PD‑L1 (‑), NRAS (‑), KRAS (‑), HRAS (‑), BRAF (‑) (‑, negative) and the microsatellite stability (MSS) were detected in the rectal cancer lesion using molecular pathological examination. Patients with primary rectal cancer and pelvic lymph node metastasis were treated with three‑dimensional conformal radiotherapy (3D‑CRT; dose, 60 Gy/30 Fr) and XELOX chemotherapy (200 mg oxaliplatin at day 1 plus 1.5 g capecitabine twice a day from day 1‑14 for a total of 5 cycles). PET/CT scan revealed that the metabolism levels of the lesion returned to normal. In addition, the routine re‑examination showed progressive improvement of tumor lesions. Until recently, the carcinoembryonic antigen (CEA) level of the male patient has been within normal range. The observation waiting method rather than the direct sequential surgical resection of the primary lesion in patients with advanced rectal cancer who achieved complete clinical remission (CCR) may provide a novel treatment method for rectal cancer. Thus, overall survival (OS) and quality of survival (QoS) differences between the two strategies need to be further verified by multicenter clinical trials.

View Figures

View References

1	Siegel R, Desantis C and Jemal A: Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117. 2014.PubMed/NCBI View Article : Google Scholar
2	Isbister WH: Audit of deﬁnitive colorectal surgery in patients with early and advanced colorectal cancer. ANZ J Surg. 72:271–274. 2002.PubMed/NCBI
3	Lee WS, Yun SH, Chun HK, Lee WY, Yun HR, Kim J, Kim K and Shim YM: Pulmonary resection for metastases from colorectal cancer: Prognostic factors and survival. Int J Colorectal Dis. 22:699–704. 2007.PubMed/NCBI View Article : Google Scholar
4	Yoo PS, Lopez-Soler RI, Longo WE and Cha CH: Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer. 6:202–207. 2006.PubMed/NCBI View Article : Google Scholar
5	Bernier L, Balyasnikova S, Tait D and Brown G: Watch-and-wait as a therapeutic strategy in rectal cancer. Curr Colorectal Cancer Rep. 14:37–55. 2018.PubMed/NCBI View Article : Google Scholar
6	Yahya J, Herzig D, Farrell M, Degnin C, Chen Y, Holland J, Brown S, Binder C, Jaboin J, Tsikitis VL, et al: Survey results of US radiation oncology providers' contextual engagement of watch-and-wait beliefs after a complete clinical response to chemoradiation in patients with local rectal cancer. J Gastrointest Oncol. 9:1127–1132. 2018.PubMed/NCBI View Article : Google Scholar
7	Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U Jr, Silva e Sousa AH Jr, Campos FG, Kiss DR and Gama-Rodrigues J: Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: Long-term results. Ann Surg. 240:711–717. 2004.PubMed/NCBI View Article : Google Scholar
8	Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, et al: Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 372:1909–1919. 2015.PubMed/NCBI View Article : Google Scholar
9	Faron M, Pignon JP, Malka D, Bourredjem A, Douillard JY, Adenis A, Elias D, Bouché O and Ducreux M: Is primary tumor resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomized trials. Eur J Cancer. 51:166–176. 2015.PubMed/NCBI View Article : Google Scholar
10	Cirocchi R, Trastulli S, Abraha I, Vettoretto N, Boselli C, Montedori A, Parisi A, Noya G and Platell C: Non-resection versus resection for an asymptomatic primary tumor in patients with unresectable stage IV colorectal cancer. Cochrane Database Syst Rev. 8(CD008997)2012.PubMed/NCBI View Article : Google Scholar
11	McCahill LE, Yothers G, Sharif S, Petrelli NJ, Lai LL, Bechar N, Giguere JK, Dakhil SR, Fehrenbacher L, Lopa SH, et al: Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: Definitive analysis of NSABP trial C-10. J Clin Oncol. 30:3223–3228. 2012.PubMed/NCBI View Article : Google Scholar
12	Temple LK, Hsieh L, Wong WD, Saltz L and Schrag D: Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol. 22:3475–3484. 2004.PubMed/NCBI View Article : Google Scholar
13	Poultsides GA, Servais EL, Saltz LB, Patil S, Kemeny NE, Guillem JG, Weiser M, Temple LK, Wong WD and Paty PB: Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol. 27:3379–3384. 2009.PubMed/NCBI View Article : Google Scholar
14	Huang S, Dang Y, Li F, Wei W, Ma Y, Qiao S and Wang Q: Biological intensity-modulated radiotherapy plus neoadjuvant chemotherapy for multiple peritoneal metastases of ovarian cancer: A case report. Oncol Lett. 9:1239–1243. 2015.PubMed/NCBI View Article : Google Scholar
15	Glynne-Jones R and Hughes R: Critical appraisal of the ‘wait and see’ approach in rectal cancer for clinical complete responders after chemoradiation. Br J Surg. 99:897–909. 2012.PubMed/NCBI View Article : Google Scholar
16	Park IJ, You YN, Agarwal A, Skibber JM, Rodriguez-Bigas MA, Eng C, Feig BW, Das P, Krishnan S, Crane CH, et al: Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol. 30:1770–1776. 2012.PubMed/NCBI View Article : Google Scholar
17	Appelt AL, Pløen J, Harling H, Jensen FS, Jensen LH, Jørgensen JC, Lindebjerg J, Rafaelsen SR and Jakobsen A: High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: A prospective observational study. Lancet Oncol. 16:919–927. 2015.PubMed/NCBI View Article : Google Scholar
18	Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC and Alberts SR: A randomized controlled trial of ﬂuorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 22:23–30. 2004.
19	Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, Celik I and Köhne CH: Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer. 48:1466–1475. 2012.PubMed/NCBI View Article : Google Scholar
20	McCawley N, Clancy C, O'Neill BD, Deasy J, McNamara DA and Burke JP: Mucinous rectal adenocarcinoma is associated with a poor response to neoadjuvant chemoradiotherapy: A systematic review and meta-analysis. Dis Colon Rectum. 59:1200–1208. 2016.PubMed/NCBI View Article : Google Scholar
21	Ren F, Weng W, Zhang Q, Tan C, Xu M, Zhang M, Wang L, Sheng W, Ni S and Huang D: Clinicopathological features and prognosis of AFP-producing colorectal cancer: A single-center analysis of 20 cases. Cancer Manag Res. 11:4557–4567. 2019.PubMed/NCBI View Article : Google Scholar
22	Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, et al: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 369:1023–1034. 2013.PubMed/NCBI View Article : Google Scholar
23	Perez RO, Habr-Gama A, Gama-Rodrigues J, Proscurshim I, Julião GP, Lynn P, Ono CR, Campos FG, Silva e Sousa AH Jr, Imperiale AR, et al: Accuracy of positron emission tomography/computed tomography and clinical assessment in the detection of complete rectal tumor regression after neoadjuvant chemoradiation: Long-term results of a prospective trial (national clinical trial 00254683). Cancer. 118:3501–3511. 2012.PubMed/NCBI View Article : Google Scholar